Cancer Genetics and Therapeutic Opportunities in Urologic Practice.
Jacob J AdashekAlex LeonardJason RoszikArjun K MentaGiannicola GenoveseVivek SubbiahPavlos MsaouelPublished in: Cancers (2020)
This article aims to summarize the current literature on genetic alterations related to tumors of the genitourinary tract. Novel associations have recently been reported between specific DNA alterations and genitourinary malignancies. The most common cause of chromosome 3p loss in clear cell renal cell carcinoma is a chromothripsis event, which concurrently generates a chromosome 5q gain. Specific patterns of clear cell renal cell carcinoma metastatic evolution have been uncovered. The first therapy targeting a specific molecular alteration has now been approved for urothelial carcinoma. Germline mutations in DNA damage repair genes and the transcription factor HOXB13 are associated with prostate cancer and may be targeted therapeutically. The genetic associations noted across different genitourinary cancers can inform potential screening approaches and guide novel targeted treatment strategies.
Keyphrases
- prostate cancer
- dna damage
- cancer therapy
- genome wide
- copy number
- transcription factor
- squamous cell carcinoma
- dna repair
- healthcare
- small cell lung cancer
- systematic review
- oxidative stress
- single molecule
- papillary thyroid
- dna methylation
- drug delivery
- climate change
- bone marrow
- squamous cell
- dna binding
- nucleic acid
- genome wide identification
- replacement therapy
- childhood cancer